MannKind Shares Down After Lung Disease Drug Trial Discontinued

Dow Jones

Nov 10, 2025

By Adriano Marchese

MannKind shares fell in premarket trading Monday after it said it has stopped a late-stage clinical trial for a new inhaled drug aimed at treating a stubborn form of lung disease.

Shares traded 9.8% lower ahead of the morning bell at $5.08.

The company said it is discontinuing the phase 3 ICoN-1 clinical trial evaluating MNKD-101 which aimed to treat refractory nontuberculous mycobacterial lung disease, a persistent, hard-to-treat lung infection caused by environmental mycobacteria that doesn't respond well to standard antibiotic therapy.

After reviewing early results from nearly 50 patients, the biopharmaceutical company found the treatment wasn't working as expected. The lack of results prompted the concerns regarding the likelihood of achieving the study's targets, it said.

The Data Safety Monitoring Board, an independent safety board, agreed the trial should end, though they confirmed the drug was safe.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

November 10, 2025 09:20 ET (14:20 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582687782"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582687782\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582687782?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582687782","market":"us","top_or_hot":-1,"title":"MannKind Shares Down After Lung Disease Drug Trial Discontinued","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  MannKind shares fell in premarket trading Monday after it said it has stopped a late-stage clinical trial for a new inhaled drug aimed at treating a stubborn form of lung disease. \n</p>\n<p>\n  Shares traded 9.8% lower ahead of the morning bell at $5.08. \n</p>\n<p>\n  The company said it is discontinuing the phase 3 ICoN-1 clinical trial evaluating MNKD-101 which aimed to treat refractory nontuberculous mycobacterial lung disease, a persistent, hard-to-treat lung infection caused by environmental mycobacteria that doesn't respond well to standard antibiotic therapy. \n</p>\n<p>\n  After reviewing early results from nearly 50 patients, the biopharmaceutical company found the treatment wasn't working as expected. The lack of results prompted the concerns regarding the likelihood of achieving the study's targets, it said. \n</p>\n<p>\n  The Data Safety Monitoring Board, an independent safety board, agreed the trial should end, though they confirmed the drug was safe. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 09:20 ET (14:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MannKind Shares Down After Lung Disease Drug Trial Discontinued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMannKind Shares Down After Lung Disease Drug Trial Discontinued\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-10 22:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  MannKind shares fell in premarket trading Monday after it said it has stopped a late-stage clinical trial for a new inhaled drug aimed at treating a stubborn form of lung disease. \n</p>\n<p>\n  Shares traded 9.8% lower ahead of the morning bell at $5.08. \n</p>\n<p>\n  The company said it is discontinuing the phase 3 ICoN-1 clinical trial evaluating MNKD-101 which aimed to treat refractory nontuberculous mycobacterial lung disease, a persistent, hard-to-treat lung infection caused by environmental mycobacteria that doesn't respond well to standard antibiotic therapy. \n</p>\n<p>\n  After reviewing early results from nearly 50 patients, the biopharmaceutical company found the treatment wasn't working as expected. The lack of results prompted the concerns regarding the likelihood of achieving the study's targets, it said. \n</p>\n<p>\n  The Data Safety Monitoring Board, an independent safety board, agreed the trial should end, though they confirmed the drug was safe. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 09:20 ET (14:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2582687782","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582687782","pubTimestamp":1762784400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"MannKind shares fell in premarket trading Monday after it said it has stopped a late-stage clinical trial for a new inhaled drug aimed at treating a stubborn form of lung disease.Shares traded 9.8% lower ahead of the morning bell at $5.08.The company said it is discontinuing the phase 3 ICoN-1 clinical trial evaluating MNKD-101 which aimed to treat refractory nontuberculous mycobacterial lung disease, a persistent, hard-to-treat lung infection caused by environmental mycobacteria that doesn't respond well to standard antibiotic therapy.After reviewing early results from nearly 50 patients, the biopharmaceutical company found the treatment wasn't working as expected. The lack of results prompted the concerns regarding the likelihood of achieving the study's targets, it said.The Data Safety Monitoring Board, an independent safety board, agreed the trial should end, though they confirmed the drug was safe.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4584":"避孕概念","MNKD":"曼恩凯德生物医疗"},"translate_title":"肺病药物试验终止后MannKind股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\n  MannKind shares fell in premarket trading Monday after it said it has stopped a late-stage clinical trial for a new inhaled drug aimed at treating a stubborn form of lung disease. \n\n\n  Shares traded 9.8% lower ahead of the morning bell at $5.08. \n\n\n  The company said it is discontinuing the phase 3 ICoN-1 clinical trial evaluating MNKD-101 which aimed to treat refractory nontuberculous mycobacterial lung disease, a persistent, hard-to-treat lung infection caused by environmental mycobacteria that doesn't respond well to standard antibiotic therapy. \n\n\n  After reviewing early results from nearly 50 patients, the biopharmaceutical company found the treatment wasn't working as expected. The lack of results prompted the concerns regarding the likelihood of achieving the study's targets, it said. \n\n\n  The Data Safety Monitoring Board, an independent safety board, agreed the trial should end, though they confirmed the drug was safe. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 09:20 ET (14:20 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}